Skip to main content

Cartesian Therapeutics, Inc.

RNAC
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001453687

No open-market purchases or sales by Cartesian Therapeutics, Inc. insiders were filed in the last 90 days; 94 institutions reported holding it in 13F filings for Q2 2026, worth $90.4M in total; no superinvestor holds it.

Q4 2024 vs. Q3 2024

How the institutions holding Cartesian Therapeutics, Inc. changed between Q3 2024 and Q4 2024.

All holders in Q4 2024All holders in Q3 2024

13F holders of RNAC: Q3 2024 compared with Q4 2024
MeasureQ3 2024Q4 2024Change
Holders6468+4
Shares6.87M6.67M−201.8K (−2.9%)
Value$110.3M$119.5M+$9.13M (+8.3%)

New holders (15)

Institutions that held Cartesian Therapeutics, Inc. at the end of Q4 2024 but not at the end of Q3 2024.

Sold out (11)

Institutions that held Cartesian Therapeutics, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.

Institutions that sold out of RNAC in Q4 2024
InstitutionShares, Q3 2024Value, Q3 2024
Great Point Partners LLC200,000$3.22M
Yale University100,000$1.61M
Armistice Capital, LLC98,565$1.59M
Schonfeld Strategic Advisors LLC50,000$797.9K
Balyasny Asset Management LLC49,497$797.9K
Lake Street Advisors Group, LLC15,822$255.1K
Ironwood Investment Management LLC14,631$235.9K
Bridgeway Capital Management, LLC10,193$164.3K
Acadian Asset Management LLC1,761$28.0K
SRS Capital Advisors, Inc.12$194
Hazlett, Burt & Watson, Inc.12$0